MX2022005628A - Regimen de dosificacion para agentes anti-bcma. - Google Patents
Regimen de dosificacion para agentes anti-bcma.Info
- Publication number
- MX2022005628A MX2022005628A MX2022005628A MX2022005628A MX2022005628A MX 2022005628 A MX2022005628 A MX 2022005628A MX 2022005628 A MX2022005628 A MX 2022005628A MX 2022005628 A MX2022005628 A MX 2022005628A MX 2022005628 A MX2022005628 A MX 2022005628A
- Authority
- MX
- Mexico
- Prior art keywords
- bcma
- antibody construct
- treatment
- agents
- domain
- Prior art date
Links
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 abstract 5
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 abstract 5
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 abstract 5
- 206010028980 Neoplasm Diseases 0.000 abstract 4
- 208000035269 cancer or benign tumor Diseases 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente invención se refiere a la dosificación y administración de agentes anti-BCMA para el tratamiento de neoplasias positivas para BCMA. Más específicamente, la presente invención se refiere a una construcción de anticuerpo que comprende un primer dominio que se une a BCMA, un segundo dominio que se une a CD3 y un tercer dominio que se extiende o mejora la semivida de la construcción de anticuerpo, para su uso en el tratamiento o mejora de una neoplasia positiva para BCMA, en donde la construcción de anticuerpo se administra a una dosis especifica en al menos un ciclo. Además, la invención se refiere a un método pare el tratamiento de una neoplasia positiva para BCMA que comprende la administración de una dosis específica de dicha construcción de anticuerpo y el uso de dicha construcción de anticuerpo para la fabricación de un medicamento para el tratamiento de una neoplasia positiva para BCMA.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19208417.6A EP3819007B1 (en) | 2019-11-11 | 2019-11-11 | Dosing regimen for anti-bcma agents |
| PCT/EP2020/062876 WO2021094000A1 (en) | 2019-11-11 | 2020-05-08 | Dosing regimen for anti-bcma agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022005628A true MX2022005628A (es) | 2022-06-14 |
Family
ID=68581157
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022005628A MX2022005628A (es) | 2019-11-11 | 2020-05-08 | Regimen de dosificacion para agentes anti-bcma. |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20210139584A1 (es) |
| EP (3) | EP3819007B1 (es) |
| JP (2) | JP2022554362A (es) |
| AU (1) | AU2020381671A1 (es) |
| CA (1) | CA3155069A1 (es) |
| DK (2) | DK3819007T3 (es) |
| ES (2) | ES2987783T3 (es) |
| FI (2) | FI3819007T3 (es) |
| HR (2) | HRP20241281T1 (es) |
| HU (2) | HUE068401T2 (es) |
| LT (2) | LT3819007T (es) |
| MA (1) | MA47888B1 (es) |
| MX (1) | MX2022005628A (es) |
| PL (2) | PL3819007T3 (es) |
| PT (2) | PT3819007T (es) |
| RS (2) | RS65943B1 (es) |
| SI (2) | SI3819007T1 (es) |
| SM (2) | SMT202400373T1 (es) |
| TW (1) | TW202118784A (es) |
| WO (1) | WO2021094000A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ795790A (en) | 2016-12-21 | 2025-11-28 | Teneobio Inc | Anti-BCMA heavy chain-only antibodies |
| EP4243936A1 (en) * | 2020-11-10 | 2023-09-20 | Amgen Inc. | Methods for administering a bcma x cd3 binding molecule |
| EP4428156A4 (en) * | 2021-12-03 | 2025-05-28 | Shandong Simcere Biopharmaceutical Co., Ltd. | ANTI-BCMA NANOBODY AND USE THEREOF |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4447A (en) | 1846-04-04 | Car- wheel | ||
| US233A (en) | 1837-06-14 | Improvement in plows | ||
| US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
| US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
| US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
| US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
| US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
| US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
| US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
| US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
| US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
| GB9206422D0 (en) | 1992-03-24 | 1992-05-06 | Bolt Sarah L | Antibody preparation |
| US7381803B1 (en) | 1992-03-27 | 2008-06-03 | Pdl Biopharma, Inc. | Humanized antibodies against CD3 |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| WO1999054440A1 (en) | 1998-04-21 | 1999-10-28 | Micromet Gesellschaft Für Biomedizinische Forschung Mbh | CD19xCD3 SPECIFIC POLYPEPTIDES AND USES THEREOF |
| GB9815909D0 (en) | 1998-07-21 | 1998-09-16 | Btg Int Ltd | Antibody preparation |
| DK1100830T3 (da) | 1998-07-28 | 2004-01-19 | Micromet Ag | Heterominiantistoffer |
| EP2292664B1 (en) | 2003-10-16 | 2016-11-23 | Amgen Research (Munich) GmbH | Multispecific deimmunized CD3-binders |
| WO2005118635A2 (en) | 2004-06-03 | 2005-12-15 | Novimmune S.A. | Anti-cd3 antibodies and methods of use thereof |
| EP3770174A1 (en) | 2005-10-11 | 2021-01-27 | Amgen Research (Munich) GmbH | Compositions comprising cross-species-specific antibodies and uses thereof |
| TW200745163A (en) | 2006-02-17 | 2007-12-16 | Syntonix Pharmaceuticals Inc | Peptides that block the binding of IgG to FcRn |
| RU2561457C2 (ru) | 2007-04-03 | 2015-08-27 | Эмджен Рисерч (Мьюник) Гмбх | Cd3-эпсилон-связывающий домен с межвидовой специфичностью |
| WO2009127691A1 (en) | 2008-04-17 | 2009-10-22 | Ablynx N.V. | Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same |
| EP2352765B1 (en) | 2008-10-01 | 2018-01-03 | Amgen Research (Munich) GmbH | Cross-species-specific single domain bispecific single chain antibody |
| JP2013509170A (ja) | 2009-10-30 | 2013-03-14 | ノボザイムス バイオファーマ デーコー アクティーゼルスカブ | アルブミン変異体 |
| CN103347893A (zh) | 2010-11-01 | 2013-10-09 | 诺维信生物制药丹麦公司 | 白蛋白变体 |
| JP2014500879A (ja) | 2010-11-16 | 2014-01-16 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｂｃｍａ発現に相関性を有する疾患を治療する因子及び方法 |
| KR20140027307A (ko) | 2011-05-05 | 2014-03-06 | 노보자임스 바이오파마 디케이 에이/에스 | 알부민 변이체 |
| US20130078250A1 (en) | 2011-08-23 | 2013-03-28 | Oliver Ast | Bispecific t cell activating antigen binding molecules |
| NO2748201T3 (es) | 2011-08-23 | 2018-05-12 | ||
| TWI679212B (zh) * | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | 針對ｂｃｍａ之e3以及ｃｄ３的結合分子 |
| EP2780364A2 (en) | 2011-11-18 | 2014-09-24 | Eleven Biotherapeutics, Inc. | Proteins with improved half-life and other properties |
| WO2013135896A1 (en) | 2012-03-16 | 2013-09-19 | Novozymes Biopharma Dk A/S | Albumin variants |
| RU2670063C2 (ru) | 2012-11-08 | 2018-10-17 | Альбумедикс А/С | Варианты альбумина |
| US20140308285A1 (en) | 2013-03-15 | 2014-10-16 | Amgen Inc. | Heterodimeric bispecific antibodies |
| EP2970484B2 (en) | 2013-03-15 | 2022-09-21 | Amgen Inc. | Heterodimeric bispecific antibodies |
| US20140302037A1 (en) | 2013-03-15 | 2014-10-09 | Amgen Inc. | BISPECIFIC-Fc MOLECULES |
| US20160257748A1 (en) | 2013-09-25 | 2016-09-08 | Amgen Inc. | V-c-fc-v-c antibody |
| EP2982692A1 (en) | 2014-08-04 | 2016-02-10 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA |
| AU2016248946C1 (en) | 2015-04-13 | 2024-10-17 | Pfizer Inc. | Therapeutic antibodies and their uses |
| EA039859B1 (ru) | 2015-07-31 | 2022-03-21 | Эмджен Рисерч (Мюник) Гмбх | Биспецифические конструкты антител, связывающие egfrviii и cd3 |
| CA2992797A1 (en) | 2015-08-03 | 2017-02-09 | Engmab Sarl | Monoclonal antibodies against bcma |
| IL298041B2 (en) | 2015-08-17 | 2025-10-01 | Janssen Pharmaceutica Nv | Anti-BCMA antibodies, bispecific antigen-binding molecules that bind BCMA and CD3, and uses thereof |
| SG11201805770UA (en) * | 2016-02-03 | 2018-08-30 | Amgen Res Munich Gmbh | BCMA and CD3 Bispecific T Cell Engaging Antibody Constructs |
| CN110167964B (zh) | 2016-11-02 | 2023-12-01 | 百时美施贵宝公司 | 组合用于治疗多发性骨髓瘤的针对bcma和cd3的双特异性抗体和免疫药物 |
| KR102425983B1 (ko) | 2017-10-13 | 2022-07-29 | 하푼 테라퓨틱스, 인크. | 삼중특이적 단백질 및 사용 방법 |
| HRP20230449T1 (hr) | 2018-05-23 | 2023-07-21 | Celgene Corporation | Antiproliferativni spojevi i bispecifična protutijela protiv bcma i cd3 za kombiniranu upotrebu |
| TWI838389B (zh) | 2018-07-19 | 2024-04-11 | 美商再生元醫藥公司 | 雙特異性抗-BCMAｘ抗-CD3抗體及其用途 |
| TW202028239A (zh) * | 2018-09-28 | 2020-08-01 | 美商安進公司 | 針對可溶性bcma之抗體 |
| EP3911371A4 (en) * | 2019-01-18 | 2023-04-26 | University of Southern California | METHODS AND COMPOSITIONS FOR IMPROVING THE SAFETY AND EFFICACY OF CELL THERAPY |
| CN119679936A (zh) | 2019-06-24 | 2025-03-25 | 诺华股份有限公司 | 针对靶向b细胞成熟抗原的多特异性抗体的给药方案和组合疗法 |
| DK3766701T3 (da) | 2019-07-18 | 2023-07-03 | Barberan Latorre Jesus Francisco | Hoved, maskine og fremgangsmåde til digital udskrivning på underlag |
| IL292704A (en) | 2019-11-05 | 2022-07-01 | Bristol Myers Squibb Co | Methods of treatment with antibodies against bcma and cd3 |
| AU2021345124A1 (en) * | 2020-09-16 | 2023-03-30 | Amgen Inc. | Methods for administering therapeutic doses of bispecific T-cell engaging molecules for the treatment of cancer |
| EP4243936A1 (en) * | 2020-11-10 | 2023-09-20 | Amgen Inc. | Methods for administering a bcma x cd3 binding molecule |
-
2019
- 2019-11-11 ES ES19208417T patent/ES2987783T3/es active Active
- 2019-11-11 FI FIEP19208417.6T patent/FI3819007T3/fi active
- 2019-11-11 HU HUE19208417A patent/HUE068401T2/hu unknown
- 2019-11-11 SI SI201930825T patent/SI3819007T1/sl unknown
- 2019-11-11 RS RS20241032A patent/RS65943B1/sr unknown
- 2019-11-11 DK DK19208417.6T patent/DK3819007T3/da active
- 2019-11-11 SM SM20240373T patent/SMT202400373T1/it unknown
- 2019-11-11 PT PT192084176T patent/PT3819007T/pt unknown
- 2019-11-11 PL PL19208417.6T patent/PL3819007T3/pl unknown
- 2019-11-11 EP EP19208417.6A patent/EP3819007B1/en active Active
- 2019-11-11 HR HRP20241281TT patent/HRP20241281T1/hr unknown
- 2019-11-11 LT LTEP19208417.6T patent/LT3819007T/lt unknown
- 2019-11-11 MA MA47888A patent/MA47888B1/fr unknown
-
2020
- 2020-05-08 DK DK20729951.2T patent/DK4058148T5/da active
- 2020-05-08 LT LTEPPCT/EP2020/062876T patent/LT4058148T/lt unknown
- 2020-05-08 MX MX2022005628A patent/MX2022005628A/es unknown
- 2020-05-08 SI SI202030419T patent/SI4058148T1/sl unknown
- 2020-05-08 PL PL20729951.2T patent/PL4058148T3/pl unknown
- 2020-05-08 WO PCT/EP2020/062876 patent/WO2021094000A1/en not_active Ceased
- 2020-05-08 ES ES20729951T patent/ES2987070T3/es active Active
- 2020-05-08 AU AU2020381671A patent/AU2020381671A1/en active Pending
- 2020-05-08 EP EP20729951.2A patent/EP4058148B1/en active Active
- 2020-05-08 JP JP2022526108A patent/JP2022554362A/ja active Pending
- 2020-05-08 RS RS20240493A patent/RS65581B1/sr unknown
- 2020-05-08 FI FIEP20729951.2T patent/FI4058148T3/fi active
- 2020-05-08 CA CA3155069A patent/CA3155069A1/en active Pending
- 2020-05-08 HU HUE20729951A patent/HUE066166T2/hu unknown
- 2020-05-08 HR HRP20240553TT patent/HRP20240553T1/hr unknown
- 2020-05-08 EP EP24162872.6A patent/EP4424709A3/en active Pending
- 2020-05-08 SM SM20240165T patent/SMT202400165T1/it unknown
- 2020-05-08 US US16/869,793 patent/US20210139584A1/en active Pending
- 2020-05-08 PT PT207299512T patent/PT4058148T/pt unknown
- 2020-05-10 TW TW109115494A patent/TW202118784A/zh unknown
-
2025
- 2025-07-31 JP JP2025128051A patent/JP2025170264A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021001083A (es) | Regimen posologico para anticuerpos biespecificos contra bcma-cd3. | |
| MX385543B (es) | Uso de un anticuerpo biespecífico para tratar cáncer de linfocitos b. | |
| MX388093B (es) | Dosis y regimen para inhibidores de la interaccion hdm2-p53. | |
| MX2022005628A (es) | Regimen de dosificacion para agentes anti-bcma. | |
| RU2017134443A (ru) | Способ лечения с применением традипитанта | |
| FI3757126T3 (fi) | Menetelmä nivelreuman hoitamiseksi il-17-antagonistien avulla | |
| RU2018101314A (ru) | Комбинированные способы лечения антагонистами pd-l1 | |
| EP4279135A3 (en) | Use of a vegf antagonist to treat diabetic retinopathy | |
| MX2015015735A (es) | Regimenes de dosificacion de inmunoconjugado anti-receptor en folato 1 (folr1). | |
| JP2018522850A5 (es) | ||
| MX2018011054A (es) | Metodos para tratar cancer de mama er+, her2-, hrg+ usando terapias de combinacion que comprenden un anticuerpo anti-erbb3. | |
| EA201690738A1 (ru) | Ингалятор сухого порошка | |
| JP2017160178A5 (es) | ||
| EA201000127A1 (ru) | Специфическая терапия и лекарственное средство на основе интегриновых лигандов для лечения рака | |
| JOP20220104A1 (ar) | نظام تجريع لعوامل مضادة لـ dll3 | |
| JP2016512564A5 (es) | ||
| MX2021004120A (es) | Regimen de dosificacion para antagonistas de tfpi. | |
| JP2014511383A5 (es) | ||
| RU2018127640A (ru) | Комбинация ингибитора hdac и антитела против pd-l1 для лечения рака яичников | |
| CO2021016606A2 (es) | Métodos para administrar un anticuerpo anti-cd38 para tratar el mieloma múltiple | |
| AR104771A1 (es) | Inhalador de polvo seco | |
| JP2017537927A5 (es) | ||
| JP2013541587A5 (es) | ||
| CY1120176T1 (el) | Μεθοδος για τη μειωση των συμπτωματων που μοιαζουν με αυτα της γριπης που συνδεονται με ενδομυϊκη χορηγηση ιντερφερονης με τη χρηση ενος σχηματος κλιμακουμενης δοσολογιας ταχειας τιτλοδοτησης | |
| MX2015009546A (es) | Dosificacion aumentada de efavirenz para el tratamiento de cancer. |